[1]张亦璐 焦丽静 许玲.基于真实世界回顾性分析中西医结合治疗对951例肺癌患者生存预后的影响[J].现代中医药,2022,1(04):119-126.[doi:10.13424/j.cnki.mtcm.2022.04.023]
　ZHANG Yilu JIAO Lijing XU Ling.Retrospective Analysis of Effect of Integrated Traditional Chinese and Western Medicine on Survival and Prognosis of 951 Patients with Lung Cancer based on Real World[J].Modern Traditional Chinese Medicine,2022,1(04):119-126.[doi:10.13424/j.cnki.mtcm.2022.04.023]
点击复制

基于真实世界回顾性分析中西医结合治疗对951例肺癌患者生存预后的影响
分享到：

《现代中医药》[ISSN:1006-6977/CN:61-1281/TN]

卷:
1
期数:
2022年04期
页码:
119-126
栏目:
临床精粹
出版日期:
2022-07-22

文章信息/Info

Title:
Retrospective Analysis of Effect of Integrated Traditional Chinese and Western Medicine on Survival and Prognosis of 951 Patients with Lung Cancer based on Real World
文章编号:
1672-0571(2022)04-0119-08
作者:
张亦璐1 焦丽静2 许玲1; 3
1.上海中医药大学附属岳阳中西医结合医院肿瘤一科，上海 200437；
2.上海中医药大学附属岳阳中西医结合医院临床免疫研究所，上海 200437；
3.上海中医药大学附属龙华医院中医肿瘤研究所，上海 200032
Author(s):
ZHANG Yilu1 JIAO Lijing2 XU Ling1; 3
1.The First Department of Oncology，Yueyang Integrated Traditional and Western Medicine Hospital，Shanghai University of Traditional Chinese Medicine，Shanghai 200437,China；
2.Institute of Clinical Immunology，Yueyang Integrated Traditional and Western Me
关键词:
关键词：真实世界; 回顾性分析; 肺癌; 中西医结合治疗; 生存预后
Keywords:
Key words：Real world; Retrospective analysis; Lung cancer; Integrated traditional Chinese and Western medicine; Survival prognosis
分类号:
R273
DOI:
10.13424/j.cnki.mtcm.2022.04.023
文献标志码:
A
摘要:
摘 要： 目的 回顾性分析中西医结合治疗对肺癌患者生存预后的影响。方法 回顾性分析某医院2003年1月—2009年8月收治的951例中西医结合治疗肺癌的病例资料，通过单因素分析法（Kaplan-Meier）及Cox回归多因素分析，分析影响生存期的独立预后因素。结果 ①951例中医药参与的治疗后，患者中位生存期：Ⅰa期45个月，Ⅰb期44个月，Ⅱa期39个月，Ⅱb期34个月，Ⅲa期19个月，Ⅲb期17个月，Ⅳ期14个月。②1~5年生存率：Ⅰ期：77%、66%、56%、51%、12%；Ⅱ期：67%、57%、49%、39%、18%；Ⅲ期：42%、26%、19%、13%、4%；Ⅳ期：31%、19%、14%、8%、2%。③单因素分析显示：性别、年龄、吸烟指数、临床分期、病理类型、辨证分型、治则、中药服用时长、手术、化疗是生存预后的影响因素（P＜0.05）；多因素分析显示：性别、年龄、临床分期、病理类型、治则、中药服用时长、手术、化疗是肺癌患者的独立预后因素（P＜0.05）。结论 中西医结合治疗肺癌患者的预后影响因素较多，其中性别、年龄、临床分期、病理类型、治则、中药服用时长、手术、化疗是影响其预后的主要因素。
Abstract:
Abstract：Objective To retrospectively analyze the effect of integrated traditional Chinese and Western medicine on the survival and prognosis of lung cancer patients. Methods The data of 951 cases of lung cancer treated with combination of Chinese and Western medicine in certain hospital from January 2003 to August 2009 were retrospectively analyzed. The independent prognostic factors affecting survival were analyzed by Kaplan-Meier and Cox regression. Results ① After the treatment with Chinese medicine，the median survival time of 951 patients was 45 months in stage Ⅰ a，44 months in stage Ⅰ b，39 months in stage Ⅱ a，34 months in stage Ⅱ b，19 months in stage Ⅲ a，17 months in stage Ⅲ b and 14 months in stage Ⅳ. ② 1-5 year survival rate: stage I: 77%，66%，56%，51%，12%；stage Ⅱ:67%，57%，49%，39%，18%；stage III: 42%，26%，19%，13%，4%；stage Ⅳ:31%，19%，14%，8%，2%. ③ Univariate analysis showed that gender，age，smoking index，clinical stage，pathological type，syndrome differentiation，treatment principle，duration of traditional Chinese medicine，operation and chemotherapy were the influencing factors of survival and prognosis (P<0.05)；multivariate analysis showed that sex，age，clinical stage，pathological type，treatment principle，duration of taking traditional Chinese medicine，operation and chemotherapy were independent prognostic factors for lung cancer patients (P<0.05).Conclusion There are many factors influencing the prognosis of lung cancer patients treated with integrated traditional Chinese and Western medicine，among which gender，age，clinical stage，pathological type，treatment principle，duration of traditional Chinese medicine，operation and chemotherapy are the main factors affecting the prognosis.Abstract：Objective To retrospectively analyze the effect of integrated traditional Chinese and Western medicine on the survival and prognosis of lung cancer patients. Methods The data of 951 cases of lung cancer treated with combination of Chinese and Western medicine in certain hospital from January 2003 to August 2009 were retrospectively analyzed. The independent prognostic factors affecting survival were analyzed by Kaplan-Meier and Cox regression. Results ① After the treatment with Chinese medicine，the median survival time of 951 patients was 45 months in stage Ⅰ a，44 months in stage Ⅰ b，39 months in stage Ⅱ a，34 months in stage Ⅱ b，19 months in stage Ⅲ a，17 months in stage Ⅲ b and 14 months in stage Ⅳ. ② 1-5 year survival rate: stage I: 77%，66%，56%，51%，12%；stage Ⅱ:67%，57%，49%，39%，18%；stage III: 42%，26%，19%，13%，4%；stage Ⅳ:31%，19%，14%，8%，2%. ③ Univariate analysis showed that gender，age，smoking index，clinical stage，pathological type，syndrome differentiation，treatment principle，duration of traditional Chinese medicine，operation and chemotherapy were the influencing factors of survival and prognosis (P<0.05)；multivariate analysis showed that sex，age，clinical stage，pathological type，treatment principle，duration of taking traditional Chinese medicine，operation and chemotherapy were independent prognostic factors for lung cancer patients (P<0.05).Conclusion There are many factors influencing the prognosis of lung cancer patients treated with integrated traditional Chinese and Western medicine，among which gender，age，clinical stage，pathological type，treatment principle，duration of traditional Chinese medicine，operation and chemotherapy are the main factors affecting the prognosis.

参考文献/References:

［1］Zeng HM，Chen WQ，Zheng RS，et al.Changing cancer survival in China during 2003-15：a pooled analysis of 17 population-based cancer registries［J］.Lancet Glob Health，2018，6(5):e555-e567.
［2］张敏璐，吴春晓，龚杨明，等.上海人群肺癌生存率分析［J］.中国癌症杂志，2017，27(5)：326-333.
［3］关念波,刘浩,林洪生.肺癌中医药治疗的研究进展及展望［J］.临床肿瘤学杂志,2013,18(3):264-267.
［4］兰央草,夏骏,王恬,等.中医药辅助化疗治疗晚期非小细胞肺癌的研究进展［J］.中国医学创新,2021,18(36):184-188.
［5］田劭丹,陈信义.中医药治疗恶性肿瘤特色与优势［J］.现代中医临床,2019,26(2):8-17.
［6］田建辉,朱飞鹏,刘苓霜,等.“以人为本”建立中医药实体瘤疗效评价标准［J］.上海中医药杂志,2012,46(9):3-6.
［7］关天宇,林洪生,侯炜,等.中医药治疗肺癌临床研究的质量控制［J］.辽宁中医药大学学报,2010,12(9):27-29.
［8］Liao Y H，Li C I，Lin C C，et al.Traditional Chinese medicine as adjunctive therapy improves the long-term survival of lung cancer patients［J］.Journal of Cancer Research & Clinical Oncology，2017.
［9］周舟,侯炜.非小细胞肺癌术后患者预后相关因素回顾性分析［J］.中华中医药杂志,2019,34(10):4820-4823.
［10］陶洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析［J］.医学信息,2018,31(12):61-64.
［11］Hsu L H,Chu N M,Liu C C,et al.Sex-associated differences in nonsmall cell lung cancer in the new era:is gender an independent prognostic factor［J］.Lung Cancer,2009,66(2):262-267
［12］朱丽华,李和根,史美育,等.非小细胞肺癌根治术后无瘤生存期影响因素分析及中药干预效果评价［J］.上海中医药杂志,2013,47(2):11－15.
［13］顾芳红,周建伟,谢立芳.清燥救肺汤加减对晚期非小细胞肺癌化疗患者生活质量和生存期的影响［J］.中国实验方剂学杂志,2020,26(11):142-147.
［14］沈佳,徐晴.解毒养阴清肺汤联合化疗在非小细胞肺癌术后应用效果观察［J］.中国中医药科技,2022,29(1):79-80.
［15］陆佳薇,陈鹏.补肾解毒汤对晚期肺癌骨转移患者疼痛状态、生存质量、肿瘤标志物的影响［J］.环球中医药,2020,13(3):439-441.
［16］华杭菊,张丽枫,任丽萍,等.补肾填精方对Lewis肺癌细胞增值及凋亡的影响［J］.光明中医,2019,34(18):2792-2794.
［17］石潇,周慧灵,刘铸,等.林洪生以软坚散结法治疗肺癌的临床经验［J］.世界中医药,2021,16(9):1482-1484.
［18］刘声,王晶,王笑民,等.软坚散结中药辅助治疗中晚期肺癌的系统评价［J］.世界中医药,2021,16(20):3027-3032,3039.
［19］李伟,刘莉,卢琼,等.益气养阴汤联合长春瑞滨+顺铂在肺癌患者中的应用效果［J］.癌症进展,2021,19(23):2420-2423.
［20］郁文越,王谦,朱博钰,等.运用益气养阴、解毒散结法治疗原发性支气管肺癌［J］.中医杂志,2021,62(22):2011-2014.

相似文献/References:

[1]曹 瑾阮绍萍 刘素蓉韩组成.偏头痛的中医证候临床研究[J].现代中医药,2017,(06):027.[doi:10.13424/j.cnki.mtcm.2017.06.011]
[2]王海静,蒲荣凤,王嘉慧,等.中西医结合治疗多囊卵巢综合征不孕症临床回顾性研究[J].现代中医药,2023,(01):121.[doi:10.13424/j.cnki.mtcm.2023.01.023]

备注/Memo

备注/Memo:
基金项目：国家中医药管理局中医药循证能力建设项目(2019XZZX-ZL004)；上海市卫健委中西医临床协作试点项目（ZXYXZ-201901）；虹口区名中医许玲学术经验传承工作室、虹口区名中医许玲北外滩社区工作站、虹口区“国医强优”三年行动计划（2018-2020年）名中医工作室（站）建设项目（HGYMZY-2018-11）；上海市中医诊疗模式创新试点建设项目-肺癌中医诊疗身心全程管理诊疗模式创新试点（ZY(2018-2020)-FWTX-6009）
更新日期/Last Update: 2022-08-03